NanoViricides (NNVC) 10-Q 21 May 18 2018 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Mar. 31, 2018	May 20, 2018
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Entity Registrant Name	NANOVIRICIDES, INC.
Entity Central Index Key	1,379,006
Current Fiscal Year End Date	--06-30
Entity Filer Category	Non-accelerated Filer
Trading Symbol	NNVC
Entity Common Stock, Shares Outstanding		68,985,000

Balance Sheets

Balance Sheets - USD ($)	Mar. 31, 2018	Jun. 30, 2017
CURRENT ASSETS:
Cash and cash equivalents	$ 10,617,837	$ 15,099,461
Prepaid expenses	332,912	190,166
Total Current Assets	10,950,749	15,289,627
PROPERTY AND EQUIPMENT
Property and equipment	14,001,766	13,776,561
Accumulated depreciation	(3,006,879)	(2,505,501)
Property and equipment, net	10,994,887	11,271,060
TRADEMARK AND PATENTS
Trademark and patents	458,954	458,954
Accumulated amortization	(81,958)	(75,756)
Trademark and patents, net	376,996	383,198
OTHER ASSETS
Security deposits	3,515	3,515
Service agreements	13,628	55,414
Other Assets	17,143	58,929
Total Assets	22,339,775	27,002,814
CURRENT LIABILITIES:
Accounts payable	195,540	135,786
Accounts payable - related parties	1,688,863	340,695
Derivative liability - Series C debentures	902,426	0
Accrued expenses	406,804	34,004
Deferred interest payable - current portion	0	166,667
Total Current Liabilities	3,193,633	4,665,518
LONG TERM LIABILITIES:
Total Liabilities	3,193,633	6,680,872
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS’ EQUITY:
Common stock, $0.001 par value; 150,000,000 shares authorized, 68,985,375 and 63,306,774 shares issued and outstanding at March 31, 2018 and June 30, 2017, respectively	68,984	63,305
Additional paid-in capital	101,113,736	95,382,979
Accumulated deficit	(82,041,102)	(75,128,691)
Total Stockholders' Equity	19,146,142	20,321,942
Total Liabilities and Stockholders' Equity	22,339,775	27,002,814
Warrant [Member]
LONG TERM LIABILITIES:
Derivative liability - warrants	0	2,015,354
Series C Debentures [Member]
CURRENT LIABILITIES:
Debentures payable - Series C, net of discount	0	3,956,153
Derivative liability - Series C debentures	0	32,213
Series A Convertible Preferred Stock [Member]
STOCKHOLDERS’ EQUITY:
Series A Convertible Preferred stock, $0.001 par value, 8,500,000 shares designated, 4,523,678 and 4,348,744 shares issued and outstanding, at March 31, 2018 and June 30, 2017, respectively	$ 4,524	$ 4,349

Balance Sheets _Parenthetical_

Balance Sheets [Parenthetical] - $ / shares	Mar. 31, 2018	Jun. 30, 2017
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	68,985,375	63,306,774
Common stock, shares, outstanding	68,985,375	63,306,774
Series A Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	8,500,000	8,500,000
Preferred stock, shares issued	4,523,678	4,348,744
Preferred stock, shares outstanding	4,523,678	4,348,744

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
OPERATING EXPENSES
Research and development	$ 1,028,938	$ 1,559,202	$ 3,570,301	$ 4,272,339
General and administrative	1,389,329	1,056,512	3,472,193	3,081,442
Total operating expenses	2,418,267	2,615,714	7,042,494	7,353,781
LOSS FROM OPERATIONS	(2,418,267)	(2,615,714)	(7,042,494)	(7,353,781)
OTHER INCOME (EXPENSE):
Interest income	23,769	17,959	73,133	43,870
Interest expense on convertible debentures	0	(165,767)	(185,275)	(655,767)
Loss on extinguishment of debt	0	(332,524)	(1,348,247)	(332,524)
Discount on convertible debentures	0	(297,662)	(359,214)	(1,124,411)
Change in fair value of derivatives	284,536	255,031	1,949,686	1,676,093
Other income (expense)	308,305	(522,963)	130,083	(392,739)
LOSS BEFORE INCOME TAX PROVISION	(2,109,962)	(3,138,677)	(6,912,411)	(7,746,520)
INCOME TAX PROVISION	0	0	0	0
NET LOSS	$ (2,109,962)	$ (3,138,677)	$ (6,912,411)	$ (7,746,520)
NET LOSS PER COMMON SHARE
- Basic	$ (0.03)	$ (0.05)	$ (0.11)	$ (0.13)
- Diluted	$ (0.03)	$ (0.05)	$ (0.11)	$ (0.13)
Weighted average common shares outstanding
- Basic	64,068,378	61,002,941	63,566,719	59,115,786
- Diluted	64,068,378	61,002,941	63,566,719	59,115,786

Statement of Changes in Stockho

Statement of Changes in Stockholders' Equity - 9 months ended Mar. 31, 2018 - USD ($)	Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance at Jun. 30, 2017	$ 20,321,942	$ 4,349	$ 63,305	$ 95,382,979	$ (75,128,691)
Balance (in shares) at Jun. 30, 2017		4,348,744	63,306,774
Common stock issued for employee compensation	65,716	$ 0	$ 71	65,645	0
Common stock issued for employee compensation (in shares)		0	71,430
Series A Preferred Stock issued for employee stock compensation	443,920	$ 50	$ 0	443,870	0
Series A Preferred Stock issued for employee stock compensation (in shares)		49,934	0
Series A Preferred Stock forfeited in Separation Agreement	0	$ (25)	$ 0	25	0
Series A Preferred Stock forfeited in Separation Agreement (in shares)		(25,000)	0
Common stock issued for Series C Debenture	4,730,000		$ 5,500	4,724,500	0
Common stock issued for Series C Debenture (in shares)			5,500,000
Series A Preferred stock issued for Series C Debenture	314,343	$ 150	$ 0	314,193	0
Series A Preferred stock issued for Series C Debenture (in shares)		150,000	0
Common stock issued for consulting and legal services rendered	81,000	$ 0	$ 76	80,924	0
Common stock issued for consulting and legal services rendered (in shares)		0	75,658
Warrants issued to Scientific Advisory Board	14,382	$ 0	$ 0	14,382	0
Warrants issued as severance payment	53,500	0	0	53,500	0
Common stock issued for Directors fees	33,750	$ 0	$ 32	33,718	0
Common stock issued for Directors fees (in shares)		0	31,513
Net loss	(6,912,411)	$ 0	$ 0	0	(6,912,411)
Balance at Mar. 31, 2018	$ 19,146,142	$ 4,524	$ 68,984	$ 101,113,736	$ (82,041,102)
Balance (in shares) at Mar. 31, 2018		4,523,678	68,985,375

Statements of Cash Flows

Statements of Cash Flows - USD ($)	9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (6,912,411)	$ (7,746,520)
Adjustments to reconcile net loss to net cash used in operating activities
Preferred shares issued as compensation	443,920	1,101,661
Common shares issued as compensation and for services	180,466	196,895
Warrants issued to Scientific Advisory Board	14,382	32,462
Warrants issued for severance agreement	53,500
Common shares issued for debenture interest	60,274	440,512
Depreciation	501,378	489,330
Amortization	6,202	6,201
Change in fair value of derivative liability	(1,949,686)	(1,676,093)
Amortization of debt discount on convertible debentures	359,214	1,124,411
Loss on extinguishment of Series C Debenture	1,348,247	0
Loss on extinguishment of Series B Debenture	0	332,524
Changes in operating assets and liabilities:
Prepaid expenses	(142,746)	2,177
Prepaid expenses - related party	0	(370,187)
Other assets	41,786	37,752
Accounts payable	59,754	16,182
Accounts payable - related party	1,348,168	(767,454)
Accrued expenses	372,800	16,668
Deferred interest payable	(41,667)	(125,001)
NET CASH USED IN OPERATING ACTIVITIES	(4,256,419)	(6,888,480)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(225,205)	(118,620)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of Series B Debentures payable	0	(1,000,000)
NET CHANGE IN CASH AND CASH EQUIVALENTS	(4,481,624)	(8,007,100)
Cash and cash equivalents at beginning of period	15,099,461	24,162,185
Cash and cash equivalents at end of period	10,617,837	16,155,085
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Interest paid	166,667	492,434
Noncash Investing and Financing Activities
Common shares issued for Series C Debenture	4,605,000	0
Common shares issued for deferred interest	125,000	83,334
Common shares issued for debenture payment	0	5,000,000
Series A Preferred Shares issued for Series C Debentures	$ 314,343	$ 0

Organization and Nature of Busi

Organization and Nature of Business	9 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Nature of Operations [Text Block]	Note 1 - Organization and Nature of Business NanoViricides, Inc. (the “Company”) was incorporated under the laws of the State of Colorado on July 25, 2000 . May 12, 2005 ., On June 1, 2005, Edot-com.com, Inc. (“ECMM”) acquired NanoViricides, Inc., a privately owned Florida corporation (“NVI”), pursuant to an Agreement and Plan of Share Exchange (the “Exchange”). NanoViricides, Inc. was incorporated under the laws of the State of Florida on May 12, 2005. Pursuant to the terms of the Exchange, ECMM acquired NVI in exchange for an aggregate of 80,000,000 100,000,000 4,000 As a result of the Exchange transaction, the former NVI stockholders held approximately 80 On June 28, 2005, NVI was merged into its parent ECMM and the separate corporate existence of NVI ceased. Effective on the same date, Edot-com.com, Inc. changed its name to NanoViricides, Inc. and its stock symbol to “NNVC”, respectively. NanoViricides, Inc. is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. NanoViricides is unique in the bio-pharma field in that it possesses its own state of the art facilities for the design, synthesis, analysis and characterization of the nanomedicines that we develop, as well as for production scale-up, and c-GMP-like production in quantities needed for human clinical trials. The biological studies such as the effectiveness, safety, bio-distribution and Pharmacokinetics/Pharmacodynamics on our drug candidates are performed by external collaborators and contract organizations. We are a company with several drugs in various stages of early development. Our drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (“TheraCour”), to which we have the necessary exclusive licenses in perpetuity. The first agreement we executed with TheraCour on September 1, 2005, gave us an exclusive, worldwide license for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV-1 and HSV-2), Influenza and Asian Bird Flu Virus. Under the License Agreements, TheraCour Pharma will receive a royalty upon sale of resulting products from NanoViricides. There is no royalty payable to date. The Company has declared its intent to license VZV (shingles) and the remaining human herpesviruses from TheraCour, and has conducted a valuation for the shingles and PHN indications. The Company intends to complete the negotiations after the appointment of a new Chief Executive Officer. The search for a new CEO with appropriate pharmaceutical industry background is ongoing and the Company is performing due diligence on the final candidates at this time. On February 15, 2010 the Company executed an Additional License Agreement with TheraCour. Pursuant to the Additional License Agreement, the Company was granted exclusive licenses, in perpetuity, for technologies, developed by TheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes. As consideration for obtaining these exclusive licenses, we agreed to pay a onetime licensing fee equal to 2,000,000 shares (adjusted for the 3.5 to 1 reverse split) of the Company’s Series A Convertible Preferred Stock (the “Series A Preferred Stock”). The Series A Preferred Stock is convertible, only in the event of a “change of control” of the Company, as defined in the designation of Series A Preferred Stock (see Note 2 for further details), into shares of the Company’s common stock at the rate of 3.5 shares of common stock for each share of Series A Preferred Stock. The Series A Preferred Stock has a preferred voting preference at the rate of nine votes per share. The Series A Preferred Stock do not contain any rights to dividends, have no liquidation preference, and are not to be amended without the Holder’s approval. The 2,000,000 2,000 The Company has declared its intent to license VZV (shingles) and the remaining human herpesviruses from TheraCour, and has conducted a valuation for the shingles and PHN indications recently. The Company intends to complete the negotiations after the appointment of a new Chief Executive Officer. The Company’s search for a new CEO with strong pharmaceutical industry background has been accelerated after Dr. Seymour’s retirement at the end of January 2018. The Executive Search Committee is currently performing due diligence on the final candidates. In the interim, the Board has appointed Anil R. Diwan, PhD, President and Chairman, as the acting CEO in January, following retirement of Dr. Eugene Seymour. His appointment as interim CEO has provided the Company with a continuous leadership. Dr. Diwan and Dr. Seymour together constituted the Executive Committee, and thus, Dr. Diwan has been involved in strategic decision-making, as well as fund-raising activities since the founding of the Company.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Note 2 - Summary of Significant Accounting Policies The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The accompanying financial statements and the information included under the heading “Management’s Discussion and Analysis or Plan of Operation” should be read in conjunction with our Company’s audited financial statements and related notes included in our Company’s Form 10-K for the fiscal year ended June 30, 2017 filed with the SEC on September 28, 2017. For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2017 filed on September 28, 2017 Basic net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock, and convertible debentures. Potentially Outstanding Dilutive Common Shares For the For the Nine Months Nine Months Ended Ended March 31, 2018 March 31, 2017 Warrants 6,958,162 6,662,428 Total potentially outstanding dilutive common shares 6,958,162 6,662,428 The Company has also issued 4,523,678 3.5 At March 31, 2018, the number of potentially dilutive shares of the Company’s common stock into which these Series A Preferred shares can be converted into is 15,832,873 For the three months ended For the nine months ended 2018 2017 2018 2017 Calculation of basic loss per share of common stock: Net loss attributable to common stockholders $ (2,109,962) $ (3,138,677) $ (6,912,411) $ (7,746,520) Denominator for basic weighted average shares of common stock 64,068,378 61,002,941 63,566,719 59,115,786 Basic loss per share of common stock $ (0.03) $ (0.05) $ (0.11) $ (0.13) Series C debentures were excluded from the fully diluted loss per share calculation for the nine months ended March 31, 2018 because their inclusion is anti-dilutive. Series B and Series C debentures were excluded from the fully diluted loss per share calculation for the three and nine months ended March 31, 2017 because their inclusion is anti-dilutive. In July 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-11. “Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features, II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. ASU 2017-11 revises the guidance for instruments with down round features in Subtopic 815-40, Derivatives and Hedging – Contracts in Entity’s Own Equity, which is considered in determining whether an equity-linked financial instrument qualifies for a scope exception from derivative accounting. An entity still is required to determine whether instruments would be classified in equity under the guidance in Subtopic 815-40 in determining whether they qualify for that scope exception. If they do qualify, freestanding instruments with down round features are no longer classified as liabilities and therefore, would not be required to be measured at fair value every reporting period. ASU 2017-11 is effective for annual and interim periods beginning December 15, 2018, and early adoption is permitted, including adoption in an interim period. ASU 2017-11 provides that upon adoption, an entity may apply this standard retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the opening balance of retaining earnings in the fiscal year and interim period adoption. The Company is currently in the process of assessing the impact of this ASU on its financial statements. In March 2016, the FASB issued ASU No. 2016-09, “Stock Compensation (topic 718)”, which includes provisions intended to simplify various aspects related to how share-based payments are accounted for and presented in the financial statements. The standard is effective for annual periods beginning after December 15, 2016, with early adoption permitted. The adoption of this standard on July 1, 2017 did not have a material effect on the Company’s financial position, results of operations or cash flows.

Financial Condition

Financial Condition	9 Months Ended
	Mar. 31, 2018
Financial Condition Disclosure [Abstract]
Financial Condition Disclosure [Text Block]	Note 3 - Financial Condition The Company’s financial statements for the interim period ended March 31, 2018 have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities and commitments in the normal course of business. The Company has an accumulated deficit at March 31, 2018 of $ 82,098,190 10,617,837 Management believes that the Company’s existing cash resources are sufficient for its operations at the current rate of expenditures to continue through May 2019. However, management believes that the available funds are insufficient for the Company’s projected work, which is beyond our normal pre-clinical development operations, leading towards an Investigational New Drug Application (IND) filing with the U.S. Food and Drug Administration (FDA), to continue through May 2019. The Company has engaged investment banks to advise it as to raising further funding as the Company progresses towards human clinical trials. The Company believes that it can adjust its business plan according to its available resources. Further, the Company believes that it will be able to raise additional funding at an opportune time as it progresses towards human clinical trials. However, the Company cannot provide assurance that its plans will not change or that changed circumstances will not result in the depletion of its capital resources more rapidly than it currently anticipates. Further, the Company cannot provide assurances that it will be able to raise additional funding in a timely manner, and if it can, that it will be on terms favorable for the Company’s current shareholders. The accompanying unaudited financial statements do not include any adjustments that may result from the outcome of such unidentified uncertainties. While the Company continues to incur significant operating losses with significant capital requirements, the Company has been able to finance its business through sale of its securities. The Company has in the past adjusted its priorities and goals in line with the cash on hand and capital availability. The Company believes it can adjust its priorities of drug development and its plan of operations as necessary, if it is unable to raise additional funds. The Company has sufficient capital to continue its business for more than one year, at the current rate of expenditure.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Mar. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 4 - Related Party Transactions Related Parties Related parties with whom the Company had transactions are: Related Parties Relationship Anil R. Diwan Chairman, President, interim CEO, significant stockholder and Director Eugene Seymour CEO Emeritus, significant stockholder TheraCour Pharma, Inc. An entity owned and controlled by a significant stockholder Milton Boniuk, MD Director and significant stockholder For the three months ended For the nine months ended March 31, March 31, March 31, March 31, Property and Equipment During the reporting period, TheraCour Pharma, Inc. acquired property and equipment on behalf of the Company from third party vendors and sold such property and equipment, at cost, to the Company $ 12,705 $ 1,589 $ 12,705 $ 19,584 As of March 31, June 30, Account Payable – Related Party Pursuant to an Exclusive License Agreement we entered into with TheraCour Pharma, Inc., (TheraCour), the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies. In consideration for obtaining this exclusive license, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of a certain portion of direct costs as a development fee and such development fees shall be due and payable in periodic installments as billed, (2) we will pay $2,000 or actual costs each month, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf. Accounts payable due TheraCour Pharma Inc. on the reporting date was $ 1,688,863 $ 340,695 For the three months ended For the nine months ended March 31, March 31, March 31, March 31, Research and Development Costs Paid to Related Parties Development fees and other costs charged by TheraCour pursuant to exclusive License Agreements between TheraCour and the Company for the development of the Company’s drug pipeline. No royalties are due TheraCour from the Company at March 31, 2018 and June 30, 2017 $ 529,031 $ 635,591 $ 2,299,712 $ 2,475,707 As of March 31, June 30, Debentures Payable to a Director Series C Convertible Debentures - Milton Boniuk $ - $ 5,000,000 On November 13, 2017 the Company entered into a Debenture Redemption Agreement with an entity controlled by Dr. Milton Boniuk to redeem the Series C Debenture (see Note 7). The related shares were issued on March 21, 2018 As of March 31, June 30, Debenture Interest Payable to a Director Coupon interest payable on $5,000,000 Series C Convertible Debentures and deferred. The deferred interest was paid quarterly over the term of the debenture commencing September 30, 2015: $ - $ 166,667 Coupon interest expense on the Series C Debenture to the IRA for Dr. Milton Boniuk for the three months ended March 31, 2018 and 2017 was $ 0 125,000 185,274 375,000 Coupon interest expense on the Series B Debentures to Dr. Milton Boniuk for the three-months ended March 31, 2017 was $ 27,178 187,178

Property and Equipment

Property and Equipment	9 Months Ended
	Mar. 31, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	Note 5 - Property and Equipment March 31, June 30, GMP Facility $ 8,011,230 $ 7,996,402 Land 260,000 260,000 Office Equipment 57,781 48,486 Furniture and Fixtures 5,607 5,607 Lab Equipment 5,667,148 5,466,066 Total Property and Equipment 14,001,766 13,776,561 Less Accumulated Depreciation (3,006,879) (2,505,501) Property and Equipment, Net $ 10,994,887 $ 11,271,060 Depreciation expense for the three months ended March 31, 2018 and 2017 were $ 168,457 163,611 501,378 489,330

Trademark and Patents

Trademark and Patents	9 Months Ended
	Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets Disclosure [Text Block]	Note 6 - Trademark and Patents March 31, June 30, Trademarks and Patents $ 458,954 $ 458,954 Less Accumulated Amortization (81,958) (75,756) Trademarks and Patents, Net $ 376,996 $ 383,198 Amortization expense amounted to $ 2,067 2,067 6,202 6,201

Convertible Debentures and Deri

Convertible Debentures and Derivatives	9 Months Ended
	Mar. 31, 2018
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Debentures - Series B The Series B debentures matured on February 1, 2017. For the three-month period ended March 31, 2017, the Company paid $ 13,589 27,178 173,589 107,178 The debt discount had been amortized to interest expense over the term of the debenture. The Company recognized amortization of the discount as an additional interest charge to “Discount on convertible debentures ” 89,165 525,263 For the three and nine months ended March 31, 2017 the change in fair value of the bifurcated embedded derivatives was ($28,284) and ($203,030), respectively, which is included in the change in fair value of derivatives on the statement of operations. Debenture - Series C On July 2, 2014 (the “Closing Date”), the Company accepted a subscription in the amount of $ 5,000,000 10 0.001 5.25 500,000 166,667 125,000 41,667 60,274 125,000 125,000 41,667 250,000 83,334 125,000 41,667 On July 2, 2014, in conjunction with the issuance of the Company’s Series C Convertible Debentures, the Company issued 187,000 1,645,606 1,152,297 1,152,297 1,879,428 The Company recognized amortization of this discount as an additional interest charge to “Discount on convertible debentures” in the amount of $ 0 208,497 359,214 599,148 150,000 The following represents the balance of the Debenture payable – Series C, net of discount at November 13, 2017 and June 30, 2017. The debt discount has been amortized to interest expense over the term of the debenture. November 13, June 30, Proceeds $ 5,000,000 $ 5,000,000 Debt Discount: Series A Preferred (1,152,297) (1,152,297) Embedded derivative (1,879,428) (1,879,428) 1,968,275 1,968,275 Accumulated amortization of debt discount 2,347,092 1,987,878 Debenture payable - Series C, net $ 4,315,367 $ 3,956,153 The Company uses a lattice model that values the compound embedded derivatives of the Series C Convertible Debenture based on a probability weighted discounted cash flow model at November 13, 2017 and June 30, 2017. The following assumptions were used for the valuation of the compound embedded derivative at November 13, 2017 and June 30, 2017: · The balance of the Series C Convertible Debenture as of November 13, 2017 and June 30, 2017 is $ 5,000,000 · The underlying stock price was used as the fair value of the common stock; The stock price decreased to $ 1.00 1.35 6.05 · The projected annual volatility was based on the Company historical volatility: · An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10% · The Holder would automatically convert the interest if the Company was not in default and its share value was equivalent to the cash value; · The Holder would automatically convert the debenture at maturity if the registration was effective and the Company was not in default. · The weighted cost of capital discount rate (based on the market value of the transaction at issuance) adjusted for changes in the risk free rate is 21.99 · Even though the shares are restricted the underlying assumption is that any restriction on resale will be removed either through registration or the passage of time at the time of issuance. The fair value of the compound embedded derivatives of the Series C Convertible Debenture at November 13, 2017 and June 30, 3017 was $ 15,449 32,213 The Company’s Series C Debenture in the amount of $ 5,000,000 5,500,000 0.001 500,000 60,274 314,726 125,000 1.00 150,000 0.001 1,348,247 150,000 364,337 314,726 0.001 314,726 684,633 15,449 Pursuant to the Redemption Agreement for the Company’s Series C Debenture, the Company issued 5,500,000 of its registered Common Stock, from its shelf registration and 150,000 On November 13, 2017, the Company recognized a liability arising from the obligation to issue the shares in settlement of the redemption of the Company’s Series C Debenture totaling $5,864,337. On March 21, 2018, when the shares where issued, the 150,000 4,730,000 The change in the fair value of the obligation to issue registered shares is recorded in the statements of operations as “change in fair value of derivatives”. For the three and nine months ended March 31, 2018, the gain from the change in fair value of the obligation to issue registered shares was $ 118,851 819,994 On March 21, 2018, when the shares were issued, the liability for the obligation to issue registered shares of $ 4,730,000 The Series A Preferred shares fair value is based on the greater of i) the converted value to common at a ratio of 1:3.5; or ii) the value of the voting rights since the Holder would lose the voting rights upon conversion. The conversion of the shares is triggered by a Change of Control. The valuations of the Series A Preferred Stock at each issuance used the following inputs: a. The common stock price was in the range $ 1.14 92 b. The calculated weighted average number of shares of common stock in the period; c. A 26.63 d. The calculated weighted average number of total voting shares and the monthly shares representing voting rights of 12.27 15.25 e. The conversion value is based on an assumption for calculation purposes only of a Change of Control in 4 3.00 2.59 f. 31.69 30.43 58.33 52.49 1.62 2.30

Equity Transactions

Equity Transactions	9 Months Ended
	Mar. 31, 2018
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	On July 21, 2015, the Board of Directors approved the employment agreement with Dr. Anil Diwan, the Company’s President. Pursuant to the terms of the employment agreement, the Company’s Board of Directors authorized the issuance of 225,000 75,000 75,000 66,786 200,358 74,317 222,950 66,786 On July 21, 2015, the Board of Directors approved the employment agreement with Dr. Eugene Seymour, the Company’s Chief Executive Officer. Pursuant to the terms of the employment agreement, the Company’s Board of Directors authorized the issuance of 225,000 75,000 75,000 The Company recognized a noncash compensation expense related to the issuance of the Series A Preferred shares for the three and nine months ended March 31, 2017 of $ 74,317 222,950 On January 27, 2018, Dr. Eugene Seymour resigned as the Chief Executive Officer and as a Director of the Company. The separation agreement calls for the vesting of 50,000 of the 75,000 that were originally scheduled to vest on June 30 per the employment agreement, 25,000 75,000 121,008 For the three and nine months ended March 31, 2018, the Company’s Board of Directors authorized the issuance of 34,502 49,934 77,492 122,555 Date Shares Value 7/31/2017 2,572 $ 8,242 8/31/2017 2,572 8,397 9/30/2017 2,572 8,588 10/31/2017 2,572 7,010 11/30/2017 2,572 6,313 12/31/2017 2,572 6,513 1/31/2018 2,572 5,552 2/28/2018 2,572 5,404 3/01/2018 26,786 60,725 03/31/2018 2,572 5,811 $ 49,934 $ 122,555 There is currently no market for the shares of Series A Preferred Stock and they can only be converted into shares of common stock upon a Change of Control of the Company as more fully described in the Certificate of Designation. The Company, therefore, estimated the fair value of the Series A Preferred stock granted to various employees and others on the date of grant. The Series A Preferred stock fair value is based on the greater of i) the converted value to common at a ratio of 1:3.5; or ii) the value of the voting rights since the Holder would lose the voting rights upon conversion. The conversion of the shares is triggered by a Change of Control. The valuations of the Series A Preferred Stock at each issuance used the following inputs: a. The common stock price was in the range $. 8225 1.14 b. The calculated weighted average number of shares of common stock in the period; c. A 26.63 d. The calculated weighted average number of total voting shares and the monthly shares representing voting rights of 12.27 15.50 The conversion value is based on an assumption for calculation purposes only of a Change of Control in 4 3.00 2.59 f. 31.69 29.78 58.33 52.33 1.53 2.30 For the nine months ended March 31, 2018, the Scientific Advisory Board (SAB) was granted fully vested warrants to purchase 11,432 1.16 1.17 1.56 4,207 14,382 Expected life (year) 4 Expected volatility 53.56-56.10 % Expected annual rate of quarterly dividends 0.00 % Risk-free rate(s) 1.67-2.30 % For the three and nine months ended March 31, 2018, the Company’s Board of Directors authorized the issuance of 29,128 75,658 27,000 81,000 For the three and nine months ended March 31, 2018, the Company’s Board of Directors authorized the issuance of 12,136 31,513 11,250 33,750 For the three and nine months ended March 31, 2018, the Company’s Board of Directors authorized the issuance of 71,430 fully vested shares of its common stock for employee compensation. The Company recognized a noncash compensation expense of $ 65,716 For the three and nine months ended March 31, 2018, the Company’s Board of Directors authorized the issuance of 250,000 250,000 53,500

Stock Warrants

Stock Warrants	9 Months Ended
	Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Note 9 - Stock Warrants Stock Warrants Stock Warrants Number of Weighted Weighted Aggregate Outstanding and exercisable at June 30, 2017 6,673,860 $ 4.93 1.36 $ - Granted 284,302 1.92 4.84 - Outstanding and exercisable at March 31, 2018 6,958,162 $ 4.81 0.84 $ - Of the above warrants, none expire in fiscal year ending June 30, 2018; 6,548,108 June 30, 2019 68,592 June 30, 2020 57,160 June 30, 2021 34,302 June 30, 2022 250,000 June 30, 2023

Fair Value Measurement

Fair Value Measurement	9 Months Ended
	Mar. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	Note 10 - Fair Value Measurement Fair value measurements At March 31, 2018 and June 30, 2017, the fair value of derivative liabilities is estimated using a lattice model that is based on the individual characteristics of our warrants, preferred and common stock, the derivative liability on the valuation date as well as assumptions for volatility, remaining expected life, risk-free interest rate and, in some cases, credit spread. The derivative liabilities are the only Level 3 fair value measures. Fair Value Measurements at March 31, 2018: (Level 1) (Level 2) (Level 3) Derivative liability – warrants $ - - $ 902,426 Total derivatives $ - $ - $ 902,426 Fair Value Measurements at June 30, 2017: (Level 1) (Level 2) (Level 3) Derivative liability – Series C debentures $ - - $ 32,213 Derivative liability – warrants - - 2,015,354 Total derivatives $ - $ - $ 2,047,567 In conjunction with the Company’s registered direct offerings of Units, consisting of the Company’s common stock and warrants, on September 12, 2013 and January 24, 2014 the Company issued 2,945,428 2,479,935 2,810,071 2,479,935 58,910 76,306 5,425,222 The Company accounts for stock purchase warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreements. Under applicable accounting guidance, stock warrants must be accounted for as derivative financial instruments if the warrants contain full-ratchet anti-dilution provisions, which preclude the warrants from being considered indexed to its own stock. The warrants described above contained a full-ratchet anti-dilution feature and are thus classified as a derivative liability. The Company used a lattice model to calculate the fair value of the derivative warrants based on a probability weighted discounted cash flow model. This model is based on future projections of the various potential outcomes. The features that were analyzed and incorporated into the model included the exercise and full reset features. The Warrants were valued as of March 31, 2018 and June 30, 2017 with the following assumptions: - The 5 5.25 6.05 - The stock price would fluctuate with the Company projected volatility. - The Holder would exercise the warrant as they become exercisable (effective registration at issuance) at target prices of the higher of 2 times 2 times - The next capital raise would fluctuate with an annual volatility. 1 Year 3/31/18 53 % 6/30/17 60 % The primary factors driving the economic value of options are stock price; stock volatility; reset events and exercise behavior. Projections of these variables over the remaining term of the warrant are either derived or based on industry averages. Based on the above, a probability was assigned to each scenario for each future period, and the appropriate derivative value was determined for each scenario. The option value was then probability weighted and discounted to the present. Fair Value Measurement Fair Value Measurement Using Significant Unobservable Inputs Derivative Derivative Beginning balance at July 1, 2017 $ 32,213 $ 2,015,354 Additions during the year - - Change in fair value (16,764) (1,112,928) Transfer in and out of Level 3 (15,449) - Balance at March 31, 2018 $ - $ 902,426

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 11 - Commitments and Contingencies Legal Proceedings There are no pending legal proceedings against the Company to the best of the Company’s knowledge as of the date hereof and to the Company’s knowledge, no action, suit or proceeding has been threatened against the Company. Employment Agreements The Company and Dr. Diwan, President and Chairman of the Board of Directors, entered into an employment agreement effective July 1, 2015 for a term of three years. Dr. Diwan’s compensation would be $ 350,000 375,000 400,000 225,000 75,000 75,000 75,000 The Company and Dr. Seymour, the Company’s former Chief Executive Officer and Director, entered into an employment agreement effective July 1, 2015, for a term of three years. Dr. Seymour’s compensation would be $ 350,000 375,000 400,000 225,000 75,000 75,000 75,000 On January 27, 2018, the Company’s Chief Executive Officer, Dr. Eugene Seymour, resigned as the Chief Executive Officer and as a Director of the Company to allow a successor with pharmaceutical experience to serve in this capacity. On April 30, 2018, the Company and Dr. Seymour finalized a Severance Agreement. Dr. Seymour has assumed the role of Chief Executive Officer Emeritus and will be available to the Company on an as-needed basis. Dr. Seymour received a severance consisting of the continued payment of his salary through December 2018, the automatic vesting of 50,000 250,000 366,667 10,000 53,500 110,000 on May 2, 2018 The Board of Directors previously commenced a search for a permanent replacement for Dr. Seymour, which is ongoing. The Board of Directors has appointed Dr. Anil Diwan, the Company’s President, as Interim Chief Executive Officer. On March 3, 2010, the Company entered into an employment agreement with Dr. Jayant Tatake to serve as Vice President of Research and Development. The employment agreement provides for a term of four years with a base salary of $ 150,000 26,786 35,715 26,786 35,715 On March 3, 2010, the Company entered into an employment agreement with Dr. Randall Barton to serve as Chief Scientific Officer. The employment agreement provided for a term of four years with a base salary of $ 150,000 35,715 35,715 On May 30, 2013, the Company entered into an Employment Agreement with Meeta Vyas to serve as its Chief Financial Officer. The employment agreement provided for a term of three years with a base salary of $ 9,000 2,572 10,800 License Agreements The Company is dependent upon its license agreement with TheraCour Pharma, Inc. (See Note 4). If the Company lost the right to utilize any of the proprietary information that is the subject of the TheraCour Pharma license agreement on which it depends, the Company will incur substantial delays and costs in development of its drug candidates. The Company intends to complete negotiation for a license for VZV, Shingles Virus, upon engagement of a new CEO. If the Company cannot come to an agreement with the Licensor, the Company will continue with the development of its currently licensed HSV-1 and HSV-2 drug candidates.

Income Taxes

Income Taxes	9 Months Ended
	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 12 – Income Taxes The Company calculates income tax expense based on an annual effective tax rate forecast, including estimates and assumptions. We have not recorded tax benefits on our loss before income taxes because we have provided for a full valuation allowance that offsets potential deferred tax assets resulting from net operating loss carry forwards, reflecting our inability to use such loss carry forwards. The Company’s effective tax rate for the nine months ended March 31, 2018 and 2017 was 0 0 The Tax Cut and Jobs Act of 2017 was enacted in December 2017. Among other things, the Act reduces the U.S. federal corporate tax rate from 34 21 5.3

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation – Interim Financial Information The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The accompanying financial statements and the information included under the heading “Management’s Discussion and Analysis or Plan of Operation” should be read in conjunction with our Company’s audited financial statements and related notes included in our Company’s Form 10-K for the fiscal year ended June 30, 2017 filed with the SEC on September 28, 2017. For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2017 filed on September 28, 2017
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Common Share Basic net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock, and convertible debentures. Potentially Outstanding Dilutive Common Shares For the For the Nine Months Nine Months Ended Ended March 31, 2018 March 31, 2017 Warrants 6,958,162 6,662,428 Total potentially outstanding dilutive common shares 6,958,162 6,662,428 The Company has also issued 4,523,678 3.5 At March 31, 2018, the number of potentially dilutive shares of the Company’s common stock into which these Series A Preferred shares can be converted into is 15,832,873 For the three months ended For the nine months ended 2018 2017 2018 2017 Calculation of basic loss per share of common stock: Net loss attributable to common stockholders $ (2,109,962) $ (3,138,677) $ (6,912,411) $ (7,746,520) Denominator for basic weighted average shares of common stock 64,068,378 61,002,941 63,566,719 59,115,786 Basic loss per share of common stock $ (0.03) $ (0.05) $ (0.11) $ (0.13) Series C debentures were excluded from the fully diluted loss per share calculation for the nine months ended March 31, 2018 because their inclusion is anti-dilutive. Series B and Series C debentures were excluded from the fully diluted loss per share calculation for the three and nine months ended March 31, 2017 because their inclusion is anti-dilutive.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements In July 2017, the FASB issued Accounting Standards Update (“ASU”) No. 2017-11. “Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features, II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. ASU 2017-11 revises the guidance for instruments with down round features in Subtopic 815-40, Derivatives and Hedging – Contracts in Entity’s Own Equity, which is considered in determining whether an equity-linked financial instrument qualifies for a scope exception from derivative accounting. An entity still is required to determine whether instruments would be classified in equity under the guidance in Subtopic 815-40 in determining whether they qualify for that scope exception. If they do qualify, freestanding instruments with down round features are no longer classified as liabilities and therefore, would not be required to be measured at fair value every reporting period. ASU 2017-11 is effective for annual and interim periods beginning December 15, 2018, and early adoption is permitted, including adoption in an interim period. ASU 2017-11 provides that upon adoption, an entity may apply this standard retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the opening balance of retaining earnings in the fiscal year and interim period adoption. The Company is currently in the process of assessing the impact of this ASU on its financial statements. In March 2016, the FASB issued ASU No. 2016-09, “Stock Compensation (topic 718)”, which includes provisions intended to simplify various aspects related to how share-based payments are accounted for and presented in the financial statements. The standard is effective for annual periods beginning after December 15, 2016, with early adoption permitted. The adoption of this standard on July 1, 2017 did not have a material effect on the Company’s financial position, results of operations or cash flows.

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following table shows the number of potentially outstanding dilutive common shares excluded from the diluted net loss per common share calculation, as they were anti-dilutive: Potentially Outstanding Dilutive Common Shares For the For the Nine Months Nine Months Ended Ended March 31, 2018 March 31, 2017 Warrants 6,958,162 6,662,428 Total potentially outstanding dilutive common shares 6,958,162 6,662,428 The following represents the basic and diluted per share calculations for loss from continuing operations: For the three months ended For the nine months ended 2018 2017 2018 2017 Calculation of basic loss per share of common stock: Net loss attributable to common stockholders $ (2,109,962) $ (3,138,677) $ (6,912,411) $ (7,746,520) Denominator for basic weighted average shares of common stock 64,068,378 61,002,941 63,566,719 59,115,786 Basic loss per share of common stock $ (0.03) $ (0.05) $ (0.11) $ (0.13)

Related Party Transactions (Tab

Related Party Transactions (Tables)	9 Months Ended
	Mar. 31, 2018
Related Party Transactions [Abstract]
Schedule of Related Party Transactions [Table Text Block]	For the three months ended For the nine months ended March 31, March 31, March 31, March 31, Property and Equipment During the reporting period, TheraCour Pharma, Inc. acquired property and equipment on behalf of the Company from third party vendors and sold such property and equipment, at cost, to the Company $ 12,705 $ 1,589 $ 12,705 $ 19,584 As of March 31, June 30, Account Payable – Related Party Pursuant to an Exclusive License Agreement we entered into with TheraCour Pharma, Inc., (TheraCour), the Company was granted exclusive licenses in perpetuity for technologies developed by TheraCour for the virus types: HIV, HCV, Herpes, Asian (bird) flu, Influenza and rabies. In consideration for obtaining this exclusive license, we agreed: (1) that TheraCour can charge its costs (direct and indirect) plus no more than 30% of a certain portion of direct costs as a development fee and such development fees shall be due and payable in periodic installments as billed, (2) we will pay $2,000 or actual costs each month, whichever is higher for other general and administrative expenses incurred by TheraCour on our behalf. Accounts payable due TheraCour Pharma Inc. on the reporting date was $ 1,688,863 $ 340,695 For the three months ended For the nine months ended March 31, March 31, March 31, March 31, Research and Development Costs Paid to Related Parties Development fees and other costs charged by TheraCour pursuant to exclusive License Agreements between TheraCour and the Company for the development of the Company’s drug pipeline. No royalties are due TheraCour from the Company at March 31, 2018 and June 30, 2017 $ 529,031 $ 635,591 $ 2,299,712 $ 2,475,707 As of March 31, June 30, Debentures Payable to a Director Series C Convertible Debentures - Milton Boniuk $ - $ 5,000,000 On November 13, 2017 the Company entered into a Debenture Redemption Agreement with an entity controlled by Dr. Milton Boniuk to redeem the Series C Debenture (see Note 7). The related shares were issued on March 21, 2018 As of March 31, June 30, Debenture Interest Payable to a Director Coupon interest payable on $5,000,000 Series C Convertible Debentures and deferred. The deferred interest was paid quarterly over the term of the debenture commencing September 30, 2015: $ - $ 166,667

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Mar. 31, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment, stated at cost, less accumulated depreciation consisted of the following: March 31, June 30, GMP Facility $ 8,011,230 $ 7,996,402 Land 260,000 260,000 Office Equipment 57,781 48,486 Furniture and Fixtures 5,607 5,607 Lab Equipment 5,667,148 5,466,066 Total Property and Equipment 14,001,766 13,776,561 Less Accumulated Depreciation (3,006,879) (2,505,501) Property and Equipment, Net $ 10,994,887 $ 11,271,060

Trademark and Patents (Tables)

Trademark and Patents (Tables)	9 Months Ended
	Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Trademark and patents, stated at cost, less accumulated amortization consisted of the following: March 31, June 30, Trademarks and Patents $ 458,954 $ 458,954 Less Accumulated Amortization (81,958) (75,756) Trademarks and Patents, Net $ 376,996 $ 383,198

Convertible Debentures and De24

Convertible Debentures and Derivatives (Tables)	9 Months Ended
	Mar. 31, 2018
Series C Debentures [Member]
Schedule of Long-term Debt Instruments [Table Text Block]	The Holder of the Series C Debenture and the Company agreed on November 13, 2017 that the Debenture would be redeemed for the Company’s common stock, as described further below. The Holder waived all early redemption payments provided for in the Debenture in consideration for 150,000 The following represents the balance of the Debenture payable – Series C, net of discount at November 13, 2017 and June 30, 2017. The debt discount has been amortized to interest expense over the term of the debenture. November 13, June 30, Proceeds $ 5,000,000 $ 5,000,000 Debt Discount: Series A Preferred (1,152,297) (1,152,297) Embedded derivative (1,879,428) (1,879,428) 1,968,275 1,968,275 Accumulated amortization of debt discount 2,347,092 1,987,878 Debenture payable - Series C, net $ 4,315,367 $ 3,956,153

Equity Transactions (Tables)

Equity Transactions (Tables)	9 Months Ended
	Mar. 31, 2018
Schedule of Stockholders Equity [Table Text Block]	The Company estimated the fair value of the warrants granted to the Scientific Advisory Board on the date of the grants using the Black-Scholes Option-Pricing Model with the following weighted-average assumptions: Expected life (year) 4 Expected volatility 53.56-56.10 % Expected annual rate of quarterly dividends 0.00 % Risk-free rate(s) 1.67-2.30 %
Series A Preferred Stock [Member]
Schedule Of Fair Value Of Stock Classified By Issuance Date [Table Text Block]	The fair value of the Series A Preferred stock was the following for the dates indicated: Date Shares Value 7/31/2017 2,572 $ 8,242 8/31/2017 2,572 8,397 9/30/2017 2,572 8,588 10/31/2017 2,572 7,010 11/30/2017 2,572 6,313 12/31/2017 2,572 6,513 1/31/2018 2,572 5,552 2/28/2018 2,572 5,404 3/01/2018 26,786 60,725 03/31/2018 2,572 5,811 $ 49,934 $ 122,555

Stock Warrants (Tables)

Stock Warrants (Tables)	9 Months Ended
	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Stock Warrants Number of Weighted Weighted Aggregate Outstanding and exercisable at June 30, 2017 6,673,860 $ 4.93 1.36 $ - Granted 284,302 1.92 4.84 - Outstanding and exercisable at March 31, 2018 6,958,162 $ 4.81 0.84 $ -

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	9 Months Ended
	Mar. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	Fair Value Measurements at March 31, 2018: (Level 1) (Level 2) (Level 3) Derivative liability – warrants $ - - $ 902,426 Total derivatives $ - $ - $ 902,426 Fair Value Measurements at June 30, 2017: (Level 1) (Level 2) (Level 3) Derivative liability – Series C debentures $ - - $ 32,213 Derivative liability – warrants - - 2,015,354 Total derivatives $ - $ - $ 2,047,567
Schedule Of Projected Annual Volatility [Table Text Block]	The projected volatility curve was based on historical volatilities of the Company for the valuation periods. The projected annual volatility for the valuation dates are: 1 Year 3/31/18 53 % 6/30/17 60 %
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following tables present the activity for liabilities measured at estimated fair value using unobservable inputs for the three months ended March 31, 2018: Fair Value Measurement Fair Value Measurement Using Significant Unobservable Inputs Derivative Derivative Beginning balance at July 1, 2017 $ 32,213 $ 2,015,354 Additions during the year - - Change in fair value (16,764) (1,112,928) Transfer in and out of Level 3 (15,449) - Balance at March 31, 2018 $ - $ 902,426

Organization and Nature of Bu28

Organization and Nature of Business (Details Textual) - USD ($)	1 Months Ended	9 Months Ended
	Feb. 15, 2010	Mar. 31, 2018	Jun. 30, 2017
Product Information [Line Items]
Entity Incorporation, State Country Name		Colorado
Entity Incorporation, Date Of Incorporation		Jul. 25, 2000
Business Acquisition, Name of Acquired Entity		Edot-com.com, Inc
Business Acquisition, Date of Acquisition Agreement		May 12, 2005
Common stock, shares issued		68,985,375	63,306,774
ECMM [Member]
Product Information [Line Items]
Common Stock Shares Issued Pro rata Basis		4,000
Stock Issued During Period, Shares, New Issues		80,000,000
Common stock, shares issued		100,000,000
Business Acquisition, Percentage of Voting Interests Acquired		80.00%
Series A Preferred Stock [Member]
Product Information [Line Items]
Preferred stock, shares issued	2,000,000	4,000
Preferred stock, value	$ 2,000
Stockholders' Equity, Reverse Stock Split	(adjusted for the 3.5 to 1 reverse split)

Summary of Significant Accoun29

Summary of Significant Accounting Policies (Details) - shares	9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,958,162	6,662,428
Warrants [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,958,162	6,662,428

Summary of Significant Accoun30

Summary of Significant Accounting Policies (Details 1) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Calculation of basic loss per share of common stock:
Net loss attributable to common stockholders	$ (2,109,962)	$ (3,138,677)	$ (6,912,411)	$ (7,746,520)
Denominator for basic weighted average shares of common stock	64,068,378	61,002,941	63,566,719	59,115,786
Basic loss per share of common stock	$ (0.03)	$ (0.05)	$ (0.11)	$ (0.13)

Summary of Significant Accoun31

Summary of Significant Accounting Policies (Details Textual) - $ / shares	9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Jun. 30, 2017
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,958,162	6,662,428
Series A Convertible Preferred Stock [Member]
Accounting Policies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 3.5
Convertible Preferred Stock, Terms of Conversion	60% or less
Preferred Stock, Shares Issued	4,523,678		4,348,744
Series A converteble preferred shares [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	15,832,873

Financial Condition (Details Te

Financial Condition (Details Textual) - USD ($)	Mar. 31, 2018	Jun. 30, 2017	Mar. 31, 2017	Jun. 30, 2016
Financial Condition [Line Items]
Cash and cash equivalents	$ 10,617,837	$ 15,099,461	$ 16,155,085	$ 24,162,185
Retained Earnings (Accumulated Deficit)	$ (82,041,102)	$ (75,128,691)

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017	Nov. 13, 2017	Jun. 30, 2017	Jul. 02, 2014
Research and development	$ 1,028,938	$ 1,559,202	$ 3,570,301	$ 4,272,339
Series C Convertible Debenture [Member]
Due to Related Parties	0		0			$ 5,000,000
Debenture Interest Payable to a Director	0		0		$ 60,274	166,667	$ 166,667
TheraCour Pharma, Inc [Member]
Net Account Payable to related party	1,688,863		1,688,863			$ 340,695
Research and development	529,031	635,591	2,299,712	2,475,707
Property, Plant and Equipment, Additions	$ 12,705	$ 1,589	$ 12,705	$ 19,584

Related Party Transactions (D34

Related Party Transactions (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Related Party Transaction [Line Items]
Related Party Transaction, Description of Transaction			costs (direct and indirect) plus no more than 30% of a certain portion of direct costs
Other General and Administrative Expense			$ 2,000
Due to Related Parties, Noncurrent	$ 4,730,000		4,730,000
Debentures payable	4,730,000		4,730,000
Debt Instrument, Face Amount	150,000		150,000
Interest Expense, Debt	0	$ 165,767	185,275	$ 655,767
Series B Convertible Debenture [Member] | Dr. Boniuk [Member]
Related Party Transaction [Line Items]
Interest Expense, Debt	27,178	27,178	187,178	187,178
Series C Convertible Debenture [Member]
Related Party Transaction [Line Items]
Debt Instrument, Face Amount	5,000,000		5,000,000
Interest Payable	5,000,000		5,000,000
Series C Convertible Debenture [Member] | Dr. Boniuk [Member]
Related Party Transaction [Line Items]
Interest Expense, Debt	$ 0	$ 125,000	$ 185,274	$ 375,000

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Mar. 31, 2018	Jun. 30, 2017
Property, Plant and Equipment [Line Items]
GMP Facility	$ 8,011,230	$ 7,996,402
Land	260,000	260,000
Office Equipment	57,781	48,486
Furniture and Fixtures	5,607	5,607
Lab Equipment	5,667,148	5,466,066
Total Property and Equipment	14,001,766	13,776,561
Less Accumulated Depreciation	(3,006,879)	(2,505,501)
Property and Equipment, Net	$ 10,994,887	$ 11,271,060

Property and Equipment (Detai36

Property and Equipment (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Property, Plant and Equipment [Line Items]
Depreciation	$ 168,457	$ 163,611	$ 501,378	$ 489,330

Trademark and Patents (Details)

Trademark and Patents (Details) - USD ($)	Mar. 31, 2018	Jun. 30, 2017
Trademarks And Patents [Line Items]
Trademarks and Patents	$ 458,954	$ 458,954
Less Accumulated Amortization	(81,958)	(75,756)
Trademarks and Patents, Net	$ 376,996	$ 383,198

Trademark and Patents (Details

Trademark and Patents (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Trademarks And Patents [Line Items]
Amortization			$ 6,202	$ 6,201
Trademark and Patents [Member]
Trademarks And Patents [Line Items]
Amortization	$ 2,067	$ 2,067	$ 6,202	$ 6,201

Convertible Debentures and De39

Convertible Debentures and Derivatives (Details) - USD ($)	Nov. 13, 2017	Jun. 30, 2017	Mar. 31, 2018
Net Proceeds From Issuance Of Debt	$ 1,968,275	$ 1,968,275
Debenture payable - Series C, net			$ 4,730,000
Series C Debentures [Member]
Proceeds	5,000,000	5,000,000
Accumulated amortization of debt discount	2,347,092	1,987,878
Debenture payable - Series C, net	4,315,367	3,956,153
Embedded derivative [Member]
Debt Discount	(1,879,428)	(1,879,428)
Series A Preferred [Member]
Debt Discount	$ (1,152,297)	$ (1,152,297)

Convertible Debentures and De40

Convertible Debentures and Derivatives (Details Textual) - USD ($)	Nov. 13, 2017	Jul. 02, 2014	Mar. 21, 2018	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017	Jun. 30, 2018	Jun. 30, 2017
Debt Instrument [Line Items]
Common stock, par value (in dollars per share)				$ 0.001		$ 0.001			$ 0.001
Debt Conversion, Converted Instrument, Amount						$ 4,605,000	$ 0
Long-term Debt, Excluding Current Maturities, Total				$ 4,730,000		4,730,000
Interest Expense, Debt				$ 0	$ 165,767	$ 185,275	655,767
Common Stock, Par Or Stated Value Per Share				$ 0.001		$ 0.001			$ 0.001
Gain (Loss) on Extinguishment of Debt				$ 0	(332,524)	$ (1,348,247)	(332,524)
Interest Paid, Net						166,667	492,434
Derivative, Gain (Loss) on Derivative, Net				$ 284,536	255,031	$ 1,949,686	1,676,093
Share price as per Redemption Agreement				1.00%		1.00%
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Change in Unrealized Gain (Loss)				$ 118,851		$ 819,994
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term						4 years
Unpaid Deferred Interest				$ 125,000		$ 125,000
Series A Preferred Stock [Member]
Debt Instrument [Line Items]
Debt Instrument, Unamortized Discount	$ 1,152,297								$ 1,152,297
Share Based Compensation Arrangement By Share Based Payment Award, Voting Rights, Percentage						26.63%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term						4 years
Series A Preferred Shares Issued For Debenture Interest Shares Issued			150,000
Common Stock [Member]
Debt Instrument [Line Items]
Stock Issued During Period, Value, New Issues						$ 5,500,000
Series A Preferred Shares Issued For Debenture Interest Shares Issued						0
Scenario, Forecast [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Amount								$ 5,000,000
Common Stock Value Issued For Debt Instrument Periodic Interest Payment								500,000
Embedded Derivative Financial Instruments [Member]
Debt Instrument [Line Items]
Debt Instrument, Unamortized Discount	$ 1,879,428								1,879,428
Maximum [Member]
Debt Instrument [Line Items]
Share Price				$ 1.14		$ 1.14
Share Based Compensation Arrangement By Share Based Payment Award, Voting Rights, Percentage						15.25%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate						56.10%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate						2.30%
Maximum [Member] | Series A Preferred Stock [Member]
Debt Instrument [Line Items]
Share Price				8,225		$ 8,225
Share Based Compensation Arrangement By Share Based Payment Award, Voting Rights, Percentage						15.50%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term						3 years
Minimum [Member]
Debt Instrument [Line Items]
Share Price				92		$ 92
Share Based Compensation Arrangement By Share Based Payment Award, Voting Rights, Percentage						12.27%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate						53.56%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate						1.67%
Minimum [Member] | Series A Preferred Stock [Member]
Debt Instrument [Line Items]
Share Price				$ 1.14		$ 1.14
Share Based Compensation Arrangement By Share Based Payment Award, Voting Rights, Percentage						12.27%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term						2 years 7 months 2 days
Series B Convertible Debentures [Member]
Debt Instrument [Line Items]
Amortization of Debt Discount (Premium)					89,165		525,263
Weighted Average Discount Rate, Percent						21.99%
Interest Paid, Net					13,589		173,589
Derivative, Gain (Loss) on Derivative, Net					(28,284)		(203,030)
Common Stock Value Issued For Debt Instrument Periodic Interest Payment					27,178		107,178
Series A Convertible Preferred Stock [Member]
Debt Instrument [Line Items]
Common stock, par value (in dollars per share)	$ 0.001
Amortization of Debt Discount (Premium)				$ 0	208,497	$ 359,214	599,148
Debt Conversion, Converted Instrument, Shares Issued	150,000	187,000
Proceeds from Convertible Debt		$ 1,645,606
Repayments of Other Debt		1,152,297
Debt Instrument, Unamortized Discount		1,152,297
Debt Conversion, Converted Instrument, Amount	$ 150,000	$ 1,879,428
Common Stock, Par Or Stated Value Per Share	$ 0.001
Gain (Loss) on Extinguishment of Debt	$ 1,348,247
Stock Issued During Period, Shares, Conversion of Convertible Securities	150,000
Stock Issued During Period, Value, Conversion of Convertible Securities	$ 364,337
Stock Issued During Period, Shares, Other	314,726
Stock Issued During Period, Value, Other	$ 314,726
Series A Convertible Preferred Stock [Member] | Scenario, Forecast [Member]
Debt Instrument [Line Items]
Debt Instrument, Unamortized Discount								684,633
Derivative Liability								15,449
Series A Convertible Preferred Stock [Member] | Maximum [Member]
Debt Instrument [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term						3 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions						31.69%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate						58.33%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate						2.30%
Series A Convertible Preferred Stock [Member] | Minimum [Member]
Debt Instrument [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term						2 years 7 months 2 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions						30.43%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate						52.49%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate						1.62%
Series C Convertible Debenture [Member]
Debt Instrument [Line Items]
Common stock, par value (in dollars per share)		$ 0.001
Debt Instrument, Convertible, Conversion Price		$ 5.25
Debt Instrument, Interest Rate, Stated Percentage		10.00%
Debt Instrument, Convertible, Carrying Amount of Equity Component		$ 5,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 6.05		$ 6.05
Long-term Debt, Excluding Current Maturities, Total	$ 5,000,000								$ 5,000,000
Share Price	$ 1								$ 1.35
Debt Instrument, Debt Default, Description of Violation or Event of Default						An event of default would occur 0% of the time, increasing 1.00% per month to a maximum of 10%
Interest Payable	$ 60,274	$ 166,667		$ 0		$ 0			$ 166,667
Debt Instrument, Periodic Payment, Interest						60,274	250,000
Common Stock, Par Or Stated Value Per Share		$ 0.001
Common Stock Value Issued For Debt Instrument Periodic Interest Payment				$ 41,667	$ 125,000	125,000	125,000
Deferred Interest Payment						125,000	83,334
Deferred Interest Payment in Cash						$ 41,667	$ 41,667
Series C Convertible Debenture [Member] | Scenario, Forecast [Member]
Debt Instrument [Line Items]
Interest Expense, Debt								$ 314,726
Series C Convertible Debenture [Member] | Embedded Derivative Financial Instruments [Member]
Debt Instrument [Line Items]
Derivative Liability, Noncurrent	$ 15,449								$ 32,213
Series C Convertible Debenture [Member] | Debenture Interest Paid [Member]
Debt Instrument [Line Items]
Interest Payable		$ 500,000

Equity Transactions (Details)

Equity Transactions (Details) - Series A Preferred Stock [Member]	9 Months Ended
	Mar. 31, 2018USD ($)shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	49,934
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 122,555
Issuance Date One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 8,242
Issuance Date Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 8,397
Issuance Date Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 8,588
Issuance Date Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 7,010
Issuance Date Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 6,313
Issuance Date Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 6,513
Issuance Date Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 5,552
Issuance Date Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 5,404
Issuance Date Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	26,786
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 60,725
Issuance Date Eleven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross | shares	2,572
Stock Issued During Period, Value, Share-based Compensation, Gross | $	$ 5,811

Equity Transactions (Details 1)

Equity Transactions (Details 1)	9 Months Ended
	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (year)	4 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	56.10%
Risk-free rate(s)	2.30%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	53.56%
Risk-free rate(s)	1.67%
Scientific Advisory Board [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected annual rate of quarterly dividends	0.00%

Equity Transactions (Details Te

Equity Transactions (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 27, 2018	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017	Jun. 30, 2017	Jun. 30, 2016	Jul. 21, 2015
Class of Stock [Line Items]
Fair Value Adjustment of Warrants		$ 4,207		$ 14,382
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term				4 years
Employee Benefits and Share-based Compensation		$ 77,492		$ 122,555
Stock Issued During Period, Value, Employee Benefit Plan				65,716
Warrants Issued for Severance Agreement				$ 53,500
Compensation Revised In Respective Of Shares				75,000
Minimum [Member]
Class of Stock [Line Items]
Share Price		$ 92		$ 92
Share Based Compensation Arrangement By Share Based Payment Award, Voting Rights, Percentage				12.27%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate				53.56%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate				1.67%
Maximum [Member]
Class of Stock [Line Items]
Share Price		$ 1.14		$ 1.14
Share Based Compensation Arrangement By Share Based Payment Award, Voting Rights, Percentage				15.25%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate				56.10%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate				2.30%
Warrant [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		250,000		250,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		250,000		250,000
Warrant [Member] | August 2021
Class of Stock [Line Items]
Number Of Common Stock To Be Issued Upon Conversion Of Warrants				11,432
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1.56		$ 1.56
Warrant [Member] | November 2021
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		1.17		1.17
Warrant [Member] | February 2022 [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1.16		$ 1.16
Director [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		29,128		29,128
Share-based Compensation, Total		$ 11,250		$ 33,750
Restricted common stock authorized for interest payable		12,136		31,513
President [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized								225,000
Share-based Compensation, Total		$ 66,786	$ 74,317	$ 200,358	222,950
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options		$ 66,786		66,786
President [Member] | Share-based Compensation Award, Tranche One [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares							75,000
President [Member] | Share-based Compensation Award, Tranche Two [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares						75,000
Chief Executive Officer [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized								225,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	50,000
Share-based Compensation, Total			$ 74,317		$ 222,950
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	25,000
Chief Executive Officer [Member] | Share-based Compensation Award, Tranche One [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares							75,000
Chief Executive Officer [Member] | Share-based Compensation Award, Tranche Two [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares						75,000
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Value, Issued For Services				$ 81,000
Series A Convertible Preferred Stock [Member] | Employee Stock Option [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period		34,502		49,934
Series A Convertible Preferred Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions				29.78%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate				52.33%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate				1.53%
Series A Convertible Preferred Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions				31.69%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate				58.33%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate				2.30%
Series A Convertible Preferred Stock [Member] | Chief Executive Officer [Member]
Class of Stock [Line Items]
Share-based Compensation, Total		$ (12,564)		$ 121,008
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Value, Issued For Services		$ 27,000
Share Based Compensation Arrangement By Share Based Payment Award, Voting Rights, Percentage				26.63%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term				4 years
Series A Preferred Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Share Price		$ 1.14		$ 1.14
Share Based Compensation Arrangement By Share Based Payment Award, Voting Rights, Percentage				12.27%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term				2 years 7 months 2 days
Series A Preferred Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Share Price		$ 8,225		$ 8,225
Share Based Compensation Arrangement By Share Based Payment Award, Voting Rights, Percentage				15.50%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term				3 years
Series A Preferred Stock [Member] | Chief Executive Officer [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	75,000
Series A Preferred Stock [Member] | Employee Compensations [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		75,658		75,658

Stock Warrants (Details)

Stock Warrants (Details) - Stock Warrants [Member] - USD ($)	9 Months Ended	12 Months Ended
	Mar. 31, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	6,673,860
Number of Shares, Granted	284,302
Number of Shares, Outstanding	6,958,162	6,673,860
Weighted Average Exercise Price per share, Outstanding (dollars per share)	$ 4.93
Weighted Average Exercise Price per share, Granted (dollars per share)	1.92
Weighted Average Exercise Price per share, Outstanding (dollars per share)	$ 4.81	$ 4.93
Weighted Average Remaining Contractual Term (years), Granted	4 years 10 months 2 days
Weighted Average Remaining Contractual Term (years), Outstanding	10 months 2 days	1 year 4 months 10 days
Aggregate Intrinsic Value, Outstanding (in dollars)	$ 0
Aggregate Intrinsic Value, Granted (in dollars)	0
Aggregate Intrinsic Value, Outstanding (in dollars)	$ 0	$ 0

Stock Warrants (Details Textual

Stock Warrants (Details Textual)	9 Months Ended
	Mar. 31, 2018shares
June 30, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	0
Warrants Expiration Date	Jun. 30, 2018
June 30, 2019 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	6,548,108
Warrants Expiration Date	Jun. 30, 2019
June 30, 2020 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	68,592
Warrants Expiration Date	Jun. 30, 2020
June 30, 2021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	57,160
Warrants Expiration Date	Jun. 30, 2021
June 30 2022 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	34,302
Warrants Expiration Date	Jun. 30, 2022
June 30, 2023 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Exercisable	250,000
Warrants Expiration Date	Jun. 30, 2023

Fair Value Measurement (Details

Fair Value Measurement (Details) - USD ($)	Mar. 31, 2018	Jun. 30, 2017
Warrant [Member]
Derivative Liability, Noncurrent	$ 0	$ 2,015,354
Fair Value, Inputs, Level 1 [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 1 [Member] | Derivative liability - Series C debentures [Member]
Derivative Liability, Noncurrent		0
Fair Value, Inputs, Level 1 [Member] | Warrant [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 2 [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 2 [Member] | Derivative liability - Series C debentures [Member]
Derivative Liability, Noncurrent		0
Fair Value, Inputs, Level 2 [Member] | Warrant [Member]
Derivative Liability, Noncurrent	0	0
Fair Value, Inputs, Level 3 [Member]
Derivative Liability, Noncurrent	902,426	2,047,567
Fair Value, Inputs, Level 3 [Member] | Derivative liability - Series C debentures [Member]
Derivative Liability, Noncurrent		32,213
Fair Value, Inputs, Level 3 [Member] | Warrant [Member]
Derivative Liability, Noncurrent	$ 902,426	$ 2,015,354

Fair Value Measurement (Detai47

Fair Value Measurement (Details 1)	9 Months Ended
	Mar. 31, 2018
One Year Ended 3/31/18
Fair Value Assumptions, Expected Volatility Rate	53.00%
One Year Ended 6/30/2017
Fair Value Assumptions, Expected Volatility Rate	60.00%

Fair Value Measurement (Detai48

Fair Value Measurement (Details 2)	9 Months Ended
	Mar. 31, 2018USD ($)
Derivative liability - Series C debentures [Member]
Beginning balance	$ 32,213
Additions during the year	0
Change in fair value	(16,764)
Transfer in and out of Level 3	(15,449)
Ending Balance	0
Warrant [Member]
Beginning balance	2,015,354
Additions during the year	0
Change in fair value	(1,112,928)
Transfer in and out of Level 3	0
Ending Balance	$ 902,426

Fair Value Measurement (Detai49

Fair Value Measurement (Details Textual) - $ / shares	1 Months Ended
	Jan. 24, 2014	Sep. 12, 2013	Mar. 31, 2018
Class of Warrant or Right, Outstanding	2,479,935	2,810,071
Warrants Issued	2,479,935	2,945,428
Placement Agents [Member]
Warrants Issued	76,306	58,910
Warrant Expiration Term	5 years	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 6.05	$ 5.25
Scientific Advisory Board [Member]
Class of Warrant or Right, Outstanding			5,425,222

Commitments and Contingencies (

Commitments and Contingencies (Details Textual) - USD ($)	Mar. 03, 2010	Apr. 30, 2018	Jan. 27, 2018	Jan. 31, 2015	May 30, 2013	Mar. 31, 2018	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015	May 02, 2018	Feb. 15, 2010
Commitments and Contingencies [Line Items]
Common stock, shares issued						68,985,375	63,306,774
Subsequent Event [Member]
Commitments and Contingencies [Line Items]
Accrued Salaries		$ 366,667
Accrued Unfront Expenses		10,000
Other Employee-related Liabilities		$ 53,500
Payments for Accrued Liabilities										$ 110,000
Warrant [Member] | Subsequent Event [Member]
Commitments and Contingencies [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		250,000
Series A Preferred Stock [Member]
Commitments and Contingencies [Line Items]
Preferred stock, shares issued						4,000					2,000,000
Series A Preferred Stock [Member] | Subsequent Event [Member]
Commitments and Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period		50,000
Chief Executive Officer [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Bonus Paid							$ 75,000	$ 75,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares			50,000
Chief Executive Officer [Member] | Share-based Compensation Award, Tranche One [Member]
Commitments and Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares								75,000
Chief Executive Officer [Member] | Year One [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense						$ 350,000
Chief Executive Officer [Member] | Year Two [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense						375,000
Chief Executive Officer [Member] | Year Three [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense						$ 400,000
Chief Executive Officer [Member] | Year Three [Member] | Share-based Compensation Award, Tranche One [Member]
Commitments and Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares									75,000
Chief Executive Officer [Member] | Series A Preferred Stock [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance						225,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares			75,000
Chief Scientific Officer [Member]
Commitments and Contingencies [Line Items]
Common stock, shares issued	35,715
Additional Common Stock Shares Issued	35,715
Increase In Base Salary	$ 150,000
President [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Bonus Paid							$ 75,000	$ 75,000
President [Member] | Share-based Compensation Award, Tranche One [Member]
Commitments and Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares								75,000
President [Member] | Year One [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense						$ 350,000
President [Member] | Year One [Member] | Share-based Compensation Award, Tranche One [Member]
Commitments and Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares									75,000
President [Member] | Year Two [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense						375,000
President [Member] | Year Three [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense						$ 400,000
President [Member] | Series A Preferred Stock [Member]
Commitments and Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance						225,000
Vice President [Member]
Commitments and Contingencies [Line Items]
Common stock, shares issued	35,715
Additional Common Stock Shares Issued	35,715
Increase In Base Salary	$ 150,000
Vice President [Member] | Series A Preferred Stock [Member]
Commitments and Contingencies [Line Items]
Preferred stock, shares issued	26,786
Additional Preferred Stock Shares Issued	26,786
Chief Financial Officer [Member]
Commitments and Contingencies [Line Items]
Increase In Base Salary				$ 10,800	$ 9,000
Chief Financial Officer [Member] | Series A Convertible Preferred Stock [Member]
Commitments and Contingencies [Line Items]
Preferred stock, shares issued					2,572

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($) $ in Millions	9 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Effective Income Tax Rate Reconciliation, Percent	0.00%	0.00%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent				34.00%
Deferred Tax Assets, Gross	$ 5.3
Scenario, Forecast [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			21.00%